Christopher G Krupp, MD | |
172 Kinsley St, Nashua, NH 03060-3648 | |
(603) 595-3061 | |
(603) 889-3774 |
Full Name | Christopher G Krupp |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 172 Kinsley St, Nashua, New Hampshire |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1689633018 | NPI | - | NPPES |
930070460 | Other | NH | RAILROAD MEDICARE |
0108705Y0NH02 | Other | NH | ANTHEM |
3136426 | Medicaid | MA | |
40005219 | Medicaid | NH |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207PE0004X | Emergency Medicine - Emergency Medical Services | 8394 (New Hampshire) | Primary |
Mailing Address | Practice Location Address |
---|---|
Christopher G Krupp, MD 172 Kinsley St, Nashua, NH 03060-3648 Ph: (603) 595-3061 | Christopher G Krupp, MD 172 Kinsley St, Nashua, NH 03060-3648 Ph: (603) 595-3061 |
News Archive
Peregrine Pharmaceuticals, Inc. today reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the initial cohort of 21 patients in the study had indicated that 11 of 17 evaluable patients with locally advanced or metastatic NSCLC achieved an objective tumor response according to RECIST criteria.
AstraZeneca today announced that the U.S. Food and Drug Administration approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.
Given Imaging Ltd. (NASDAQ: GIVN) today announced encouraging results from a trial that validated new features of the company's second-generation PillCamĀ® Colon video capsule and system. The Company also announced that it has obtained the CE mark for the sale of PillCam COLON 2 in Europe.
Exposure to radioactive iodines, mainly iodine 131 (I-131), in childhood is associated with an increased risk of thyroid cancer. Importantly, both iodine deficiency and supplementation appear to modify this risk, according to a new study in the May 18 issue of the Journal of the National Cancer Institute.
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received approval for three antiretroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization's (WHO) Prequalification of Medicines Programme. The products include:
› Verified 7 days ago
Peter J Gould, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 172 Kinsley St, Nashua, NH 03060 Phone: 603-882-3000 Fax: 603-889-3774 | |
Peter L Row, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 172 Kinsley St, Emergency Dept, Nashua, NH 03060 Phone: 603-595-3061 Fax: 603-889-3774 | |
Eric J Hoffman, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 172 Kinsley St, Nashua, NH 03060 Phone: 603-595-3061 Fax: 603-889-3774 | |
William Loverro, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 172 Kinsley St, Nashua, NH 03060 Phone: 603-595-3061 Fax: 603-889-3774 | |
Daniel F Weidner, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 8 Prospect St, Nashua, NH 03060 Phone: 603-577-2500 | |
Norman Kossayda, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 172 Kinsley St, Nashua, NH 03060 Phone: 603-595-3061 Fax: 603-889-3774 | |
Melissa Wu, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 8 Prospect Street, Southern New Hampshire Medical Center, Nashua, NH 03061 Phone: 603-577-2273 |